Navigation Links
Targeted Anticancer Drugs - In Vitro Assessment and Non-Invasive Imaging of Patient and Tumor Status Will Determine Clinical and Commercial Success
Date:6/11/2008

New Medicine's Oncology KnowledgeBASE (nm/OK) tracks the development and use of patient and tumor assessment methodologies that represent one of the

most unique opportunities in the oncology field

LAGUNA NIGUEL, Calif., June 11 /PRNewswire/ -- Drug development in oncology is at the threshold of a new era that may finally fulfill the promise of cancer becoming a chronic disease. It is becoming apparent that in order to successfully treat patients with cancer it is necessary to accurately profile their disease and closely and continuously monitor its development. Coupling the use of targeted anticancer agents with patient selection and monitoring using highly specific in vitro tests and/or noninvasive imaging approaches is creating a unique and powerful method for the effective treatment of cancer.

New Medicine's Oncology KnowledgeBASE (nm/OK) that has anticipated this trend is a unique resource of every aspect of patient assessment to customize cancer treatment. A unique functionality of nm/OK allows users to specifically retrieve information regarding diagnostic/prognostic approaches by developer and cancer indication; target assessment (overexpression, amplification, mutation, methylation status) by drug, marker, and clinical trial protocol; and biomarkers for clinical trial surrogate endpoints, among others.

There are over 1,000 molecular targets linked to some aspect of neoplasia currently in preclinical or clinical development or on the market. Among the approximately 500 novel molecularly targeted agents that have been evaluated in clinical trials (multitargeted agents may appear in several groups) are:

41 agents targeting the vascular endothelial growth factor (VEGF) pathway

18 agents targeting the ErBb family (EGFr, HEr2, etc.)

13 agents targeting the Aurora kinase family

11 histone deacetylase inhibitors (HDAC)

13 agents targeting PDGF/PDGFr

11 agents targeting various heat
'/>"/>

SOURCE New Medicine, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Study suggests brain tumors need treatment with multiple targeted drugs
2. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
3. Research suggests targeted treatment strategies for lupus
4. S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
5. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Assessment of Its Phase I/II Trial of tgAAC94 for Inflammatory Arthritis
6. Gleevec, the targeted cancer pill, delivers more good news to patients
7. OHSU Cancer Institute researcher develops test for targeted therapy in acute myeloid leukemia
8. Light powered platinum more targeted and 80 times more powerful than similar cancer treatments
9. A major step toward a more targeted treatment for auto-immune diseases?
10. NeoStrata Clinical Findings Reveal Benefits of Combining Glycolic Acid Peels and Targeted Home Care With Microdermabrasion for Optimized Treatment of Photodamaged Skin
11. New study of targeted therapies for breast cancer -- model for global clinical trials

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)...wswire/ -- Chiltern International Limited (Chilter...providing clinical development and staffing servic...es the appointment of Dr. Sharon Moore as Execut...ffairs. Dr. Moore is based at Chiltern,s Bristol, ...ian with 15 years of industry experience. Prior to...
(Date:12/3/2009)...ec. 3 For California,s 3.4 million...lity remains one of the most significant threats t...t also their business,s viability. ,, "As the ...l, owners of small businesses are recognizing the ...nhanced disability coverage," said Michael Hagedo...
(Date:12/3/2009)...to an understanding of how accurate DNA replicatio...ancer and genetic diseases ,, DETROIT, Dec. 3 ... have for the first time observed the movement of ...ates nucleotides one by one. More significantly, t... they speculate is part of the proofreading proces...
(Date:12/3/2009)...ocedures on young women caused by outdated HPV tes...on December 11 for blocking new technology. , ... 2, 2009 -- Now the American College of Obstetric...sive cancer workup procedure, also known as colpo...o some women who have received the procedure . How...
(Date:12/3/2009)...ewswire/ -- According to the World Health Organiza...lu") has reached a pandemic level. Over 500,000 c...,500 fatalities. Since there is no longer a requi...numbers undoubtedly understate the real situation....prnh/20091203/NY20654 ) ,, There are currently...
Breaking Medicine News(10 mins):Health News:Chiltern Names Dr. Sharon Moore as Executive VP, Global Quality & Medical Affairs 2Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 2Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 3Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 4Health News:Wayne State Researchers Report a Possible 'Proofreading' Step in DNA Synthesis by Observing Single Molecules of DNA Polymerase 2Health News:Wayne State Researchers Report a Possible 'Proofreading' Step in DNA Synthesis by Observing Single Molecules of DNA Polymerase 3Health News:Harmful Procedures on Young Women Caused by Outdated HPV test, not by Pap Test 2Health News:Buchang Global Health Forum 2009: An Innovative Approach for Management of H1N1 Swine Flu 2
...onetics Europe, BRAINTREE, Mass., Nov. 8 Haemone...l Gordon will join the company,effective November ...ordon,will have responsibility for European operat...and. He will also join,Haemonetics, global Operati...
...-FirstCall/ -- China Sky One,Medical, Inc. (OTC Bu...distributor of pharmaceutical, medicinal and diagn...s completed the previously announced amendment to,...ded September 30, 2007, management determined that...
...VES, RANCHO CORDOVA, Calif., Nov. 8 ThermoGenesi...novative products and,services that process, store...ells for treatment of disease and injury, today re...4.3 million for the first quarter of fiscal,2007. ...
...stribution Channels, OWINGS MILLS, Md., Nov. 8 M...quarter results for the period ended,September 30,...ast reported,revenue of $21.8 million, an 11% incr... versus $1,455,000 or $0.11 per basic,share ($0.11...
...troke and heart attacks, revised label warns , ...S. Food and Drug Administration on Thursday approv...iesis-stimulating agents, which are drugs used to ...ts with chronic kidney failure. Those dangers incl...
... ),announced today that it will present at the Cre...uesday, November 13, 2007 at 11:00 a.m. Eastern,Ti... Senior Vice President,Wyeth and President, Wyeth ... the conference. Wyeth is one of the world,s larg...
Other Medicine News:Health News:Haemonetics Appoints Executive Leadership of European Operations 2Health News:China Sky One Medical Completes Previously Announced Amendment to 2006 Form 10KSB 2Health News:ThermoGenesis Corp. Reports First Quarter 2008 Results 2Health News:ThermoGenesis Corp. Reports First Quarter 2008 Results 3Health News:ThermoGenesis Corp. Reports First Quarter 2008 Results 4Health News:ThermoGenesis Corp. Reports First Quarter 2008 Results 5Health News:ThermoGenesis Corp. Reports First Quarter 2008 Results 6Health News:ThermoGenesis Corp. Reports First Quarter 2008 Results 7Health News:Medifast Announces Third-Quarter 2007 Results 2Health News:Medifast Announces Third-Quarter 2007 Results 3Health News:Medifast Announces Third-Quarter 2007 Results 4Health News:Medifast Announces Third-Quarter 2007 Results 5Health News:Medifast Announces Third-Quarter 2007 Results 6Health News:Medifast Announces Third-Quarter 2007 Results 7Health News:Medifast Announces Third-Quarter 2007 Results 8Health News:FDA Issues New Warnings for Anemia Drugs 2Health News:FDA Issues New Warnings for Anemia Drugs 3
(Date:12/3/2009)...Dec. 3 Radiology imaging leader ME...egration capabilities at the November 2009 Radiolo...ect.PACS(TM) product, enabling the first radiolog...est release in the company,s newly branded Certeg...tp://www.newscom.com/cgi-bin/prnh/20091203/NE20631...
(Date:12/3/2009)... ParagonRx, a Delaware-based compa...and optimal medication use, will host a free webin...ce on REMS - Risk Evaluation Mitigation Strategy -...management. Dr. Gary Slatko, chief medical office...gement programs, will lead the one-hour program be...
(Date:12/3/2009)...mark and SAN DIEGO, California, December 3 /PRNews...s miR-122, a microRNA Important for,Hepatitis C Vi...patitis C,Virus in the Bloodstream in Chimpanzees ..., - SPC3649 Demonstrates Efficacy With No E... Events in the Treated Animals - Signaling a Poten...
Breaking Medicine Technology:MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 2New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 4New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 5Paraplegic Takes Leap of Faith for Treatment in India 50232 1Paraplegic Takes Leap of Faith for Treatment in India 50232 2Data Demonstrates Long Term Reduction In Seizure Frequency With Novel Once Daily Anti Epileptic Zebinix 28R 29 4660 1Data Demonstrates Long Term Reduction In Seizure Frequency With Novel Once Daily Anti Epileptic Zebinix 28R 29 4660 2Data Demonstrates Long Term Reduction In Seizure Frequency With Novel Once Daily Anti Epileptic Zebinix 28R 29 4660 3Data Demonstrates Long Term Reduction In Seizure Frequency With Novel Once Daily Anti Epileptic Zebinix 28R 29 4660 4Data Demonstrates Long Term Reduction In Seizure Frequency With Novel Once Daily Anti Epileptic Zebinix 28R 29 4660 5Data Demonstrates Long Term Reduction In Seizure Frequency With Novel Once Daily Anti Epileptic Zebinix 28R 29 4660 6Data Demonstrates Long Term Reduction In Seizure Frequency With Novel Once Daily Anti Epileptic Zebinix 28R 29 4660 7Ozone depletes oil seed rape productivity 9037 1
...rine Achieves Milestone as Third Phase II Trial in...ient Enrollment and Dosing -, TUSTIN, Calif., Aug...HM ) today announced that patient screening,and do...luate the safety,and efficacy of bavituximab in co...ced breast cancer. The new trial is the second Pha...
..., Va., Aug. 8 Innocoll, Inc., a privately-held,bi...atient has been dosed,in the first of three ongoin...owned subsidiary, Innocoll Technologies Ltd, to in...for the management of,post-operative pain., Innoc...ble and fully,bioresorbable matrix of purified fib...
Other Medicine Technology:Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer 2Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer 3Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer 4Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain 2Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain 3Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain 4
Premier Thumb Spica
FREEDOM® Memory Thumb Spica
QualCraft™ Gamekeeper Thumb Stabilizer
...dom® CMC ThumbFit™ reduces joint instabi...ofile splint is remarkably comfortable and easy fo... CHT and Robert V. Sypher Jr., MD, FAAOS, develope...plaints of discomfort and impaired hand function f...
Medicine Products: